Sage Therapeutics Inc Reports Results For The Quarter Ended March 31: Earnings Summary

Sage Therapeutics

29/04/2025 22:01

SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.01​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.80.  The mean expectation of seventeen analysts for the quarter was for a loss of 100 cents per share. Wall Street expected results to range from $-1.20 to -49 cents per share.

Revenue rose 78% to $14.06 million from a year ago; analysts expected $14.14 million.

SAGE Therapeutics Inc's reported EPS for the quarter was a loss of $1.01​.

The company reported a quarterly loss of $62.21 million.

SAGE Therapeutics Inc shares had fallen by 2.3% this quarter and gained 43.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 15.5% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 15 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for SAGE Therapeutics Inc is $8.00

This summary was machine generated from LSEG data April 29 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-1.00
-1.01
Missed
Dec. 31 2024
-1.51
-1.56
Missed
Sep. 30 2024
-1.53
-1.53
Met
Jun. 30 2024
-1.66
-1.70
Missed